Articles tagged "Antibodies"

2016 American Transplant Congress
Baseline Donor Specific Antibody (DSA) More Predictive of Chronic Antibody Mediated Rejection (CAMR) Than the Change in DSA Over Time.
D. Mitema,¹ W. Cheungpasitporn,¹ M. Stegall,¹ F. Cosio,¹ M. Gandhi,² C. Schinstock.¹
¹Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN; ²Division of Transfusion Medicine, Mayo Clinic, Rochester, MN.
Introduction: Although therapies are available to at least temporarily reduce DSA, the change in DSA naturally post-transplant remains unknown. We aim to study the serial…
2016 American Transplant Congress
Acquired Down-Regulation of B Cell Function Induced by Donor Blood Group Antigens After ABO-Incompatible Kidney Transplantation.
M. Tasaki,¹ K. Saito,¹ Y. Nakagawa,¹ N. Imai,² T. Aoki,³ M. Kamimura,³ K. Takahashi,¹ Y. Tomita.¹
¹Division of Urology, Department of Regenerative & Transplant Medicine, Niigata Graduate School of Medical and Dental Sciences, Niigata, Japan; ²Division of Clinical Nephrology and Rheumatology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan; ³Division of Transfusion Medicine and Regenerative Medicine Bioscience Medical Center, Niigata University Medical and Dental Hospital, Niigata, Japan.
Background: The long-term of B cell immunobiology against donor blood group antigen has not been elucidated in ABO incompatible kidney transplantation (ABOi KTx).Methods: The antibody…
2016 American Transplant Congress
Designing and Synthesizing a Novel Highly Selective Immunoproteasome Inhibitor That Promotes Long Term Heart Allograft Acceptance While Reducing Plasma Cells and Donor Specific Antibodies.
A. Mihali,¹ E. Sula Karreci,¹ A. Kurdi,³ L. Riella,¹ Y. Kawano,³ H. Fan,² P. Singh,² I. Ghobrial,³ C. Nathan,² G. Lin,² J. Azzi.¹
¹Transplantation Research Center, Harvard Medical School, Boston; ²Department of Microbiology and Immunology, Weill Cornell Medicine, NY; ³Department of Medical Oncology, Dana-Farber Cancer Institute, Boston.
Antibody mediated rejection (AMR) is one of the most important barriers to improving long-term transplant outcomes. Traditional therapies for AMR do not deplete the source…
2016 American Transplant Congress
Positive Lymphocytes Flow Cytometry Crossmatch Due to AT1r Antibodies in Absence of HLA-DSA.
M. Ramirez,¹ D. Kershaw,² Y. Huang,² J. Magee,³ M. Samaniego,² T. Williams,¹ D. Schauss,¹ T. Franks,¹ Y. Kleyman,¹ D. Ramon.¹
¹Department of Pathology, University of Michigan School of Medicine, Ann Arbor, MI; ²Department of Internal Medicine, UMICH, Ann Arbor; ³Department of Surgery, UMICH, Ann Arbor.
The angiotensin II type 1 receptor (AT1r) plays a key role in the renin-angiotensin system. Anti-AT1R antibodies (Abs) have been associated with both acute and…
2016 American Transplant Congress
Poor HLA Matching May Reduce the Beneficial Effect of ABOi Pairs Entering the Paired and Pooled Scheme.
M. Willicombe, C. Lawrence, R. Charif, A. McLean, J. Galliford, D. Taube.
Imperial College Renal and Transplant Centre, Hammersmith Hospital, London, United Kingdom.
Introduction: Paired/pooled donation (PPD) facilitates transplantation between UK donor-recipient pairs who are either HLA or blood group incompatible, in whom transplantation is either contraindicated or…
2016 American Transplant Congress
Preformed Antibodies Against AT₁R and EDNRA Correlate with Rejection Post-Transplant.
A. Gareau,¹ C. Wiebe,^1,2 D. Pochinco,² I. Gibson,³ D. Rush,¹ P. Nickerson.^1,2,4
¹Internal Medicine, University of Manitoba, Winnipeg, MB, Canada; ²Diagnostic Services of Manitoba, Winnipeg, MB, Canada; ³Pathology, University of Manitoba, Winnipeg, MB, Canada; ⁴Immunology, University of Manitoba, Winnipeg, MB, Canada.
Studies have investigated the potential pathogenic effects of non-HLA antibodies (Ab), with a few reporting that Ab against the angiotensin II type 1 receptor (AT1R)…
2016 American Transplant Congress
Reduced Incidence and Level of De Novo Donor-Specific Antibodies in Belatacept-Treated vs. Cyclosporine-Treated Patients: Final Results from BENEFIT.
R. Bray,¹ H. Gebel,¹ R. Townsend,² M. Polinsky,² L. Yang,² U. Meier-Kriesche,² C. Larsen.¹
¹Emory University, Atlanta, GA; ²Bristol-Myers Squibb, Lawrenceville, NJ.
Background: The presence of donor-specific antibodies (DSA) has been associated with an increased risk of antibody-mediated rejection and graft failure. Mean fluorescence intensity (MFI) is…
2016 American Transplant Congress
Angiotensin II Type 1 Receptor Antibodies Are Associated with Allograft Loss in Pediatric Renal Transplantation.
M. Pearl,¹ Q. Zhang,² M. Palma Diaz,³ J. Grotts,⁴ J. Brook,⁴ D. Gjertson,² P. Weng,¹ E. Reed,² E. Tsai.¹
¹Pediatrics, University of California-Los Angeles, Los Angeles, CA; ²Pathology and Laboratory Medicine, University of California-Los Angeles, Los Angeles, CA; ³Anatomic & Clinical Pathology, University of California-Los Angeles, Los Angeles, CA; ⁴Biostatistics, University of California-Los Angeles, Los Angeles, CA.
Background: Angiotensin II type 1 receptor antibody (AT1R-Ab) is associated with vascular injury and allograft failure in adult kidney transplantation. Its role in pediatric transplantation…
2016 American Transplant Congress
Urine Cell-Free Supernatant Metabolites Diagnostic of Antibody Mediated Rejection in Kidney Allografts.
M. Alkadi,¹ J. Lee,¹ D. Dadhania,¹ T. Muthukumar,¹ C. Snopkowski,¹ C. Li,¹ S. Salvatore,¹ S. Seshan,¹ K. Suhre,² M. Suthanthiran.¹
¹Weill Cornell Medicine, NY; ²Weill Cornell Medical College-Qatar, Doha, Qatar.
Introduction:Urine cell-free supernatant metabolite profiles provide a unique opportunity to interrogate intra-graft processes and have distinguished acute cellular rejection from no rejection in the Clinical…
2016 American Transplant Congress
Bone Allograft: An Unusual Cause of Sensitization.
J. Bloch,¹ V. Elsermans,² F. Provôt,¹ A. Lionet,¹ L. Wajbrot-Houzé,³ C. Noel,¹ M. Hazzan.¹
¹Service de Néphologie et Transplantation, CHRU, Hopital Claude Huriez, Lille, France; ²Institut d'Immunologie, CHRU, Centre de Biologie et Pathologie, Lille, France; ³Service de Néphrologie, Centre Hospitalier de Béthune, Béthune, France.
We report the case of a 33 year-old female patient who started hemodialysis in 2009 because of end stage renal disease of unknown etiology. When…